264 related articles for article (PubMed ID: 27834631)
41. Inhibitory receptor FcγRIIb mediates the effects of IgG on a phagosome acidification and a sequential dephosphorylation system comprising SHIPs and Inpp4a.
Segawa T; Hazeki K; Nigorikawa K; Nukuda A; Tanizawa T; Miyamoto K; Morioka S; Hazeki O
Innate Immun; 2017 May; 23(4):401-409. PubMed ID: 28409542
[TBL] [Abstract][Full Text] [Related]
42. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
[TBL] [Abstract][Full Text] [Related]
43. Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.
Liao D; Miller EC; Teravskis PJ
Eur J Neurosci; 2014 Apr; 39(7):1202-13. PubMed ID: 24712999
[TBL] [Abstract][Full Text] [Related]
44. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease.
Oddo S; Caccamo A; Green KN; Liang K; Tran L; Chen Y; Leslie FM; LaFerla FM
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):3046-51. PubMed ID: 15705720
[TBL] [Abstract][Full Text] [Related]
45. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions.
Higuchi M; Iwata N; Saido TC
Biochim Biophys Acta; 2005 Aug; 1751(1):60-7. PubMed ID: 16054018
[TBL] [Abstract][Full Text] [Related]
46. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
47. Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function -- role of glucose metabolism and insulin signalling.
Rhein V; Eckert A
Arch Physiol Biochem; 2007 Jun; 113(3):131-41. PubMed ID: 17922309
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
49. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
Oddo S; Billings L; Kesslak JP; Cribbs DH; LaFerla FM
Neuron; 2004 Aug; 43(3):321-32. PubMed ID: 15294141
[TBL] [Abstract][Full Text] [Related]
50. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
Matsuoka Y; Gray AJ; Hirata-Fukae C; Minami SS; Waterhouse EG; Mattson MP; LaFerla FM; Gozes I; Aisen PS
J Mol Neurosci; 2007; 31(2):165-70. PubMed ID: 17478890
[TBL] [Abstract][Full Text] [Related]
51. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model.
Qi L; Ke L; Liu X; Liao L; Ke S; Liu X; Wang Y; Lin X; Zhou Y; Wu L; Chen Z; Liu L
Eur J Pharmacol; 2016 Jul; 783():23-32. PubMed ID: 27131827
[TBL] [Abstract][Full Text] [Related]
52. Brain Amyloid-β Plays an Initiating Role in the Pathophysiological Process of the PS1V97L-Tg Mouse Model of Alzheimer's Disease.
Wang W; Lu L; Wu QQ; Jia JP
J Alzheimers Dis; 2016 Apr; 52(3):1089-99. PubMed ID: 27079718
[TBL] [Abstract][Full Text] [Related]
53. Plexin-A4 mediates amyloid-β-induced tau pathology in Alzheimer's disease animal model.
Chung S; Yang J; Kim HJ; Hwang EM; Lee W; Suh K; Choi H; Mook-Jung I
Prog Neurobiol; 2021 Aug; 203():102075. PubMed ID: 34004220
[TBL] [Abstract][Full Text] [Related]
54. Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide.
Gardner LE; White JD; Eimerbrink MJ; Boehm GW; Chumley MJ
Neuroscience; 2016 Sep; 331():72-7. PubMed ID: 27320209
[TBL] [Abstract][Full Text] [Related]
55. The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer's disease.
Zhao X; Xiong L; She L; Li L; Huang P; Liang G
Biomed Pharmacother; 2022 Jul; 151():113188. PubMed ID: 35676788
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies.
Zheng Q; Kebede MT; Kemeh MM; Islam S; Lee B; Bleck SD; Wurfl LA; Lazo ND
Molecules; 2019 Jun; 24(12):. PubMed ID: 31234523
[TBL] [Abstract][Full Text] [Related]
57. Diosmin reduces cerebral Aβ levels, tau hyperphosphorylation, neuroinflammation, and cognitive impairment in the 3xTg-AD mice.
Sawmiller D; Habib A; Li S; Darlington D; Hou H; Tian J; Shytle RD; Smith A; Giunta B; Mori T; Tan J
J Neuroimmunol; 2016 Oct; 299():98-106. PubMed ID: 27725131
[TBL] [Abstract][Full Text] [Related]
58. Assessment of tau phosphorylation and β-amyloid pathology in human drug-resistant epilepsy.
Aroor A; Nguyen P; Li Y; Das R; Lugo JN; Brewster AL
Epilepsia Open; 2023 Jun; 8(2):609-622. PubMed ID: 37052232
[TBL] [Abstract][Full Text] [Related]
59. Drugs for Targeted Therapies of Alzheimer's Disease.
Tam C; Wong JH; Ng TB; Tsui SKW; Zuo T
Curr Med Chem; 2019; 26(2):335-359. PubMed ID: 29714133
[TBL] [Abstract][Full Text] [Related]
60. Korean red ginseng polysaccharide as a potential therapeutic agent targeting tau pathology in Alzheimer's disease.
Kim S; Shin SJ; Nam Y; Park YH; Kim BH; Park HH; Kumar V; Yoo DH; Lee YY; Hoe HS; Moon M
Int J Biol Macromol; 2024 Apr; 263(Pt 2):130516. PubMed ID: 38423419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
